Radioligand Therapy: Pluvicto Uptake and Treatment Capacity | Oncology Modality Intelligence

Description

List of Tables

Radioligand therapy reached Japan's reimbursement system in November 2025, when Pluvicto was listed on the NHI price schedule for PSMA-positive metastatic castration-resistant prostate cancer. The listing converted a modality that Japanese physicians had watched from abroad for years into a payable service, and it exposed the real constraint immediately: the drug is not the bottleneck - the system around it is. Radioligand therapy requires licensed handling of lutetium-177, shielded rooms, certified facilities, nuclear medicine and urology coordination, and a referral network that identifies patients and moves them to the handful of sites able to treat them.

The tension is between a strong demand signal and thin infrastructure. Japan's prostate cancer burden is rising on the aging curve, global supply of Lu-177 and the next-wave actinium-225 isotopes is contested by every developer at once, and the major pharmaceutical houses - Novartis with its Advanced Accelerator Applications platform, Lilly through POINT Biopharma, Bristol Myers Squibb through RayzeBio, and AstraZeneca through Fusion Pharmaceuticals - are all building pipelines that will compete for the same certified beds Japan has yet to build. Site certification criteria, radiation-safety regulation, isotope import logistics, and the economics of running an RLT suite under NHI fees are each unsettled in ways that will determine how fast capacity forms.

This report maps the Pluvicto launch and the capacity question around it. It explains the VISION and PSMAfore evidence base and how it shaped the Japanese label, details the regulatory and facility requirements for Lu-177 administration, and profiles the supply side: isotope producers ITM, Curium, and Orano Med; imaging partners Lantheus and Telix; domestic players PDRadiopharma and Nihon Medi-Physics; and the pipeline programs that will seek the same infrastructure. Chapters address referral flows, site economics, competing RLT programs, and the diagnostic-imaging layer that gates patient selection.

The report serves radiopharmaceutical developers planning Japan entry or expansion, hospital operators evaluating an RLT investment, imaging and isotope suppliers, and investors tracking the modality. It provides the regulatory, infrastructural, and commercial detail needed to judge where Japanese RLT capacity will exist and who will control it.

Scope and Coverage: The report covers Pluvicto's Japan approval, NHI listing, and evidence base; the regulatory and facility requirements for radioligand administration; isotope supply and imaging infrastructure; and pipeline RLT programs relevant to Japan. It profiles Novartis, Lilly, Bristol Myers Squibb, AstraZeneca, ITM, Curium, Orano Med, Telix, Lantheus, PDRadiopharma, and Nihon Medi-Physics.

Report Highlights:

Explains Pluvicto's Japanese label, NHI listing pathway, and supporting trial programs
Details facility certification, radiation-safety, and handling requirements for Lu-177 therapy
Maps referral flows from urology and oncology to certified RLT sites
Profiles global and domestic isotope supply and imaging infrastructure players
Covers competing RLT pipelines, including Ac-225 and Pb-212 alpha-emitter programs
Analyzes site economics under NHI fees and capacity-formation scenarios

Product Code: JPH-027

Table of Content

1. Executive Summary

2. Radioligand Therapy: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Novartis (CH) - Pluvicto originator; Advanced Accelerator Applications radioligand platform
Eli Lilly (US) - POINT Biopharma acquisition for the PNT2002 RLT program
Bristol Myers Squibb (US) - RayzeBio acquisition for an Ac-225 pipeline
AstraZeneca (UK) - Fusion Pharmaceuticals acquisition for Ac-225 conjugates
ITM Isotope Technologies (DE) - Lu-177 supply and the ITM-11 RLT program
Perspective Therapeutics (US) - alpha-emitter RLT platform
Telix (AU) - PSMA imaging and RLT pipeline
Bayer (DE) - Xofigo and actinium RLT heritage
Curium (FR) - nuclear medicine and isotope supply
Orano Med (FR) - Pb-212 alpha-emitter platform
Lantheus (US) - Pylarify PSMA PET imaging supporting RLT patient selection
PDRadiopharma (JP) - PeptiDream subsidiary; domestic Japanese radiopharma developer
Nihon Medi-Physics (JP) - domestic radiopharmaceutical supplier

Product Code: JPH-027

List of Tables

Table 1. Radioligand Therapy Mechanism: PSMA Targeting and Lu-177 Delivery
Table 2. Pluvicto (Lutetium-177 Vipivotide Tetraxetan): Product Profile and Japanese Label
Table 3. VISION Trial: Design, Population, and Regulatory Role
Table 4. PSMAfore Trial: Design and Its Place in Treatment Sequencing
Table 5. Japanese Bridging and Pharmacovigilance Requirements for Pluvicto
Table 6. Pluvicto NHI Listing Process: Price Setting and Conditions
Table 7. Radiation-Safety Regulation for Lu-177 Administration in Japan
Table 8. Facility Certification Requirements for Radioligand Therapy Sites
Table 9. Shielded-Room and Waste-Management Specifications for RLT Wards
Table 10. Nuclear Medicine and Urology Co-Management Model for RLT Patients
Table 11. Referral Pathway Design from Community Urology to Certified Centers
Table 12. PSMA PET Imaging Requirements for Pluvicto Patient Selection
Table 13. Lantheus Pylarify and PSMA PET Supply in Japan
Table 14. Telix Illuccix and Alternative PSMA Imaging Agents: Japan Status
Table 15. Isotope Supply Chain for Lu-177: Reactor Production to Hospital Delivery
Table 16. ITM Isotope Supply Programs and ITM-11 Pipeline
Table 17. Curium Nuclear Medicine and Isotope Supply Operations
Table 18. Orano Med Pb-212 Alpha-Emitter Platform
Table 19. Novartis Advanced Accelerator Applications: RLT Platform and Pipeline
Table 20. Lilly POINT Biopharma Acquisition: PNT2002 and SPLASH Program
Table 21. Bristol Myers Squibb RayzeBio Acquisition: Ac-225 Pipeline
Table 22. AstraZeneca Fusion Pharmaceuticals Acquisition: Ac-225 Conjugate Programs
Table 23. Perspective Therapeutics Alpha-Emitter RLT Platform
Table 24. Bayer Xofigo and Actinium RLT Heritage
Table 25. PDRadiopharma Domestic Radiopharmaceutical Development
Table 26. Nihon Medi-Physics Domestic Radiopharmaceutical Supply Role
Table 27. Competing RLT Pipeline Programs Relevant to Japan: Asset Map
Table 28. RLT Programs in Neuroendocrine Tumors: Lutathera and Follow-Ons
Table 29. Japan Radiopharmaceutical Regulatory Framework: PMDA and Nuclear Regulation Authority Roles
Table 30. Site Certification Pipeline: Hospitals Preparing RLT Capability
Table 31. Site Economics of an RLT Suite Under NHI Fees
Table 32. Staffing Requirements: Radiopharmacists, Technologists, and Physicians
Table 33. Isotope Import Logistics and Decay-Management Planning
Table 34. Patient Eligibility Criteria Under the Japanese Label and Guidelines
Table 35. Interaction Between RLT and ARPI Sequencing in Japanese Practice
Table 36. Hospital Investment Decision Framework for RLT Capability
Table 37. Regional Access and Patient Travel Burden Analysis Framework
Table 38. International RLT Capacity Benchmarks: Germany, US, and Australia
Table 39. Radiopharmacy Compounding and Quality-Control Requirements
Table 40. Safety Monitoring and Adverse-Event Management Protocols for RLT
Table 41. Clinical Trial Activity in Japan for Pipeline RLT Assets
Table 42. Partnership and Licensing Structures in Japanese Radiopharma
Table 43. Scenario Framework: RLT Capacity Formation Paths
Table 44. Risk Register: Isotope Shortage, Site Bottlenecks, and Safety Events
Table 45. Indicator Dashboard for RLT Market Monitoring
Table 46. Due-Diligence Checklist for RLT Site Investments
Table 47. Stakeholder Positions on RLT Infrastructure Policy
Table 48. Alpha vs Beta Emitter Programs: Differentiation Framework
Table 49. Future RLT Indications Beyond Prostate Cancer: Program Scan
Table 50. Analytical Appendix: Regulatory Documents and Data Sources

List of Figures

Figure 1. PSMA-Targeted Radioligand Mechanism Diagram
Figure 2. Pluvicto Product Profile and Administration Cycle
Figure 3. VISION and PSMAfore Trial Design Schematics
Figure 4. Pluvicto Japan Approval and NHI Listing Timeline
Figure 5. Radiation-Safety Regulatory Map for Lu-177 in Japan
Figure 6. RLT Facility Certification Requirement Checklist
Figure 7. Shielded-Room and Waste-Management Layout Schematic
Figure 8. Co-Management Model Between Nuclear Medicine and Urology
Figure 9. Referral Pathway Diagram to Certified RLT Centers
Figure 10. PSMA PET Patient-Selection Workflow
Figure 11. PSMA Imaging Agent Landscape in Japan
Figure 12. Lu-177 Supply Chain from Reactor to Bedside
Figure 13. ITM, Curium, and Orano Med Supply Positioning
Figure 14. Novartis AAA Platform and Pipeline Map
Figure 15. Lilly POINT Biopharma Program Tree
Figure 16. Bristol Myers Squibb RayzeBio Ac-225 Pipeline Map
Figure 17. AstraZeneca Fusion Pharmaceuticals Program Map
Figure 18. Domestic Players: PDRadiopharma and Nihon Medi-Physics Roles
Figure 19. Competing RLT Pipeline Asset Map for Japan
Figure 20. Lutathera and NET RLT Program Context
Figure 21. PMDA and Nuclear Regulation Authority Jurisdiction Map
Figure 22. Site Certification Pipeline Heat-Map Framework
Figure 23. RLT Suite Cost and Revenue Structure Diagram
Figure 24. RLT Staffing Model by Role
Figure 25. Isotope Import Logistics and Decay Timeline
Figure 26. Patient Eligibility Flow Under the Japanese Label
Figure 27. RLT and ARPI Sequencing Framework
Figure 28. Hospital Investment Decision Tree for RLT
Figure 29. Regional Access and Travel Burden Framework
Figure 30. Germany, US, and Australia RLT Capacity Benchmarks
Figure 31. Radiopharmacy Quality-Control Workflow
Figure 32. RLT Safety Monitoring Protocol Flow
Figure 33. Japan Clinical Trial Map for Pipeline RLT Assets
Figure 34. Radiopharma Partnership and Licensing Structures
Figure 35. Scenario Tree: RLT Capacity Formation
Figure 36. Risk Map: Isotope, Site, and Safety Risks
Figure 37. RLT Market Monitoring Dashboard
Figure 38. Due-Diligence Flow for RLT Site Investments
Figure 39. Stakeholder Position Map on RLT Policy
Figure 40. Alpha vs Beta Emitter Differentiation Framework
Figure 41. Future RLT Indication Scan Beyond Prostate Cancer
Figure 42. Imaging-to-Therapy Theranostic Loop Diagram
Figure 43. Capacity Planning Model for a National RLT Network
Figure 44. Physician Training Pathway for RLT Delivery
Figure 45. Patient Experience Map Through an RLT Treatment Course
Figure 46. Competition Between RLT Programs for Certified Sites
Figure 47. Reimbursement Flow for an RLT Treatment Episode
Figure 48. Investor KPI Dashboard for the Japan RLT Theme
Figure 49. Synthesis: Conditions for RLT Scale-Up in Japan
Figure 50. Report Roadmap: Chapter Linkages to Reader Decisions

Radioligand Therapy: Pluvicto Uptake and Treatment Capacity | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Radioligand Therapy: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures